{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:22:14Z","timestamp":1785363734156,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40256-024-00652-6","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T15:02:38Z","timestamp":1718031758000},"page":"469-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Towards the Fifth Pillar for the Treatment of Heart Failure with Reduced Ejection Fraction: Vericiguat in Older and Complex Patients"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-4121","authenticated-orcid":false,"given":"Luigi","family":"Spadafora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Sarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Betti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Cammisotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bartimoccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sabouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Biondi","family":"Zoccai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Frati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Sciarretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"issue":"36","key":"652_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"2","key":"652_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1053\/hj.1999.v137.95495","volume":"137","author":"GA Haldeman","year":"1999","unstructured":"Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999;137(2):352\u201360. https:\/\/doi.org\/10.1053\/hj.1999.v137.95495.","journal-title":"Am Heart J"},{"issue":"6","key":"652_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.rec.2022.05.005","volume":"75","author":"TA McDonagh","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed). 2022;75(6):523. https:\/\/doi.org\/10.1016\/j.rec.2022.05.005.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"5\u20136","key":"652_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10354-021-00903-0","volume":"172","author":"P Dovjak","year":"2022","unstructured":"Dovjak P. Polypharmacy in elderly people. Wien Med Wochenschr. 2022;172(5\u20136):109\u201313. https:\/\/doi.org\/10.1007\/s10354-021-00903-0.","journal-title":"Wien Med Wochenschr"},{"issue":"1","key":"652_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.24969\/hvt.2023.367","volume":"7","author":"S Cacciatore","year":"2023","unstructured":"Cacciatore S, Martone AM, Landi F, Tosato M. Acute coronary syndrome in older adults: an update from the 2022 Scientific Statement by the American Heart Association. Heart Vessels Transplant. 2023;7(1):7\u201310. https:\/\/doi.org\/10.24969\/hvt.2023.367.","journal-title":"Heart Vessels Transplant"},{"issue":"6","key":"652_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2023.04.057","volume":"82","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Bauersachs J, Brugts JJ, et al. Management of worsening heart failure with reduced ejection fraction: JACC focus seminar 3\/3. J Am Coll Cardiol. 2023;82(6):559\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.057.","journal-title":"J Am Coll Cardiol"},{"key":"652_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031574","author":"A D'Amato","year":"2024","unstructured":"D\u2019Amato A, Prosperi S, Severino P, et al. Current approaches to worsening heart failure: pathophysiological and molecular insights. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25031574.","journal-title":"Int J Mol Sci"},{"issue":"10367","key":"652_CR8","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1.","journal-title":"Lancet"},{"key":"652_CR9","doi-asserted-by":"publisher","first-page":"1554875","DOI":"10.1155\/2022\/1554875","volume":"2022","author":"R Chiles","year":"2022","unstructured":"Chiles R, Al-Horani RA. Vericiguat: a new hope for heart failure patients. Cardiovasc Ther. 2022;2022:1554875. https:\/\/doi.org\/10.1155\/2022\/1554875.","journal-title":"Cardiovasc Ther"},{"issue":"2","key":"652_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10741-012-9323-1","volume":"18","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, Marti CN, Sabbah HN, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013;18(2):123\u201334. https:\/\/doi.org\/10.1007\/s10741-012-9323-1.","journal-title":"Heart Fail Rev"},{"issue":"5","key":"652_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/10600280211041384","volume":"56","author":"N Campbell","year":"2022","unstructured":"Campbell N, Kalabalik-Hoganson J, Frey K. Vericiguat: a novel oral soluble guanylate cyclase stimulator for the treatment of heart failure. Ann Pharmacother. 2022;56(5):600\u20138. https:\/\/doi.org\/10.1177\/10600280211041384.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"652_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/CRD.0000000000000431","volume":"31","author":"R Gupta","year":"2023","unstructured":"Gupta R, Lin M, Maitz T, et al. Vericiguat: a novel soluble guanylate cyclase stimulator for use in patients with heart failure. Cardiol Rev. 2023;31(2):87\u201392. https:\/\/doi.org\/10.1097\/CRD.0000000000000431.","journal-title":"Cardiol Rev"},{"issue":"14","key":"652_CR13","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s40265-021-01586-y","volume":"81","author":"AJS Coats","year":"2021","unstructured":"Coats AJS, Tolppanen H. Drug treatment of heart failure with reduced ejection fraction: defining the role of vericiguat. Drugs. 2021;81(14):1599\u2013604. https:\/\/doi.org\/10.1007\/s40265-021-01586-y.","journal-title":"Drugs"},{"issue":"5","key":"652_CR14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jama.2020.10262","volume":"324","author":"SP Murphy","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488\u2013504. https:\/\/doi.org\/10.1001\/jama.2020.10262.","journal-title":"JAMA"},{"key":"652_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102471","author":"F Vannuccini","year":"2022","unstructured":"Vannuccini F, Campora A, Barilli M, Palazzuoli A. Vericiguat in heart failure: characteristics, scientific evidence and potential clinical applications. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10102471.","journal-title":"Biomedicines"},{"issue":"22","key":"652_CR16","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1093\/eurheartj\/ehq396","volume":"31","author":"T Munzel","year":"2010","unstructured":"Munzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J. 2010;31(22):2741\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehq396.","journal-title":"Eur Heart J"},{"issue":"4","key":"652_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, D\u2019Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1209657.","journal-title":"N Engl J Med"},{"key":"652_CR18","volume-title":"VERQUVO\u00ae (vericiguat): EU summary of product characteristics","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. VERQUVO\u00ae (vericiguat): EU summary of product characteristics. Amsterdam: European Medicines Agency; 2021."},{"issue":"4","key":"652_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1714\/4004.39824","volume":"24","author":"SA Di Fusco","year":"2023","unstructured":"Di Fusco SA, Alonzo A, Aimo A, et al. ANMCO Position paper: Vericiguat use in heart failure: from evidence to place in therapy [in Italian]. G Ital Cardiol (Rome). 2023;24(4):323\u201331. https:\/\/doi.org\/10.1714\/4004.39824.","journal-title":"G Ital Cardiol (Rome)"},{"issue":"3","key":"652_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.cardfail.2022.10.431","volume":"29","author":"VN Rao","year":"2023","unstructured":"Rao VN, Diez J, Gustafsson F, et al. Practical patient care considerations with use of vericiguat after worsening heart failure events. J Card Fail. 2023;29(3):389\u2013402. https:\/\/doi.org\/10.1016\/j.cardfail.2022.10.431.","journal-title":"J Card Fail"},{"issue":"22","key":"652_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021094","volume":"10","author":"CSP Lam","year":"2021","unstructured":"Lam CSP, Mulder H, Lopatin Y, et al. Blood pressure and safety events with vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021;10(22): e021094. https:\/\/doi.org\/10.1161\/JAHA.121.021094.","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"652_CR22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1161\/CIRCULATIONAHA.121.056797","volume":"144","author":"JA Ezekowitz","year":"2021","unstructured":"Ezekowitz JA, Zheng Y, Cohen-Solal A, et al. Hemoglobin and clinical outcomes in the vericiguat global study in patients with heart failure and reduced ejection fraction (VICTORIA). Circulation. 2021;144(18):1489\u201399. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056797.","journal-title":"Circulation"},{"issue":"8","key":"652_CR23","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/ejhf.2221","volume":"23","author":"AA Voors","year":"2021","unstructured":"Voors AA, Mulder H, Reyes E, et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. Eur J Heart Fail. 2021;23(8):1313\u201321. https:\/\/doi.org\/10.1002\/ejhf.2221.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"652_CR24","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/ejhf.2608","volume":"24","author":"M Senni","year":"2022","unstructured":"Senni M, Alemayehu WG, Sim D, et al. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan: insights from the VICTORIA trial. Eur J Heart Fail. 2022;24(9):1614\u201322. https:\/\/doi.org\/10.1002\/ejhf.2608.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"652_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jchf.2022.11.007","volume":"11","author":"MS Khan","year":"2023","unstructured":"Khan MS, Xu H, Fonarow GC, et al. Applicability of vericiguat to patients hospitalized for heart failure in the United States. JACC Heart Fail. 2023;11(2):211\u201323. https:\/\/doi.org\/10.1016\/j.jchf.2022.11.007.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"652_CR26","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00228-024-03654-0","volume":"80","author":"F Kerwagen","year":"2024","unstructured":"Kerwagen F, Ohlmeier C, Evers T, et al. Real-world characteristics and use patterns of patients treated with vericiguat: a nationwide longitudinal cohort study in Germany. Eur J Clin Pharmacol. 2024;80(6):931\u201340. https:\/\/doi.org\/10.1007\/s00228-024-03654-0.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"652_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010599","volume":"16","author":"JA Ezekowitz","year":"2023","unstructured":"Ezekowitz JA, McMullan CJ, Westerhout CM, et al. Background medical therapy and clinical outcomes from the VICTORIA Trial. Circ Heart Fail. 2023;16(9): e010599. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.010599.","journal-title":"Circ Heart Fail"},{"issue":"9","key":"652_CR28","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2174\/138945012802002348","volume":"13","author":"PR Evora","year":"2012","unstructured":"Evora PR, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview. Curr Drug Targets. 2012;13(9):1207\u201314. https:\/\/doi.org\/10.2174\/138945012802002348.","journal-title":"Curr Drug Targets"},{"issue":"6","key":"652_CR29","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s10741-022-10239-5","volume":"27","author":"F Triposkiadis","year":"2022","unstructured":"Triposkiadis F, Xanthopoulos A, Skoularigis J, Starling RC. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure. Heart Fail Rev. 2022;27(6):1991\u20132003. https:\/\/doi.org\/10.1007\/s10741-022-10239-5.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"652_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mayocpiqo.2018.12.006","volume":"3","author":"C Premer","year":"2019","unstructured":"Premer C, Kanelidis AJ, Hare JM, Schulman IH. Rethinking endothelial dysfunction as a crucial target in fighting heart failure. Mayo Clin Proc Innov Qual Outcomes. 2019;3(1):1\u201313. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2018.12.006.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"652_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","volume":"21","author":"JP Stasch","year":"2015","unstructured":"Stasch JP, Schlossmann J, Hocher B. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr Opin Pharmacol. 2015;21:95\u2013104. https:\/\/doi.org\/10.1016\/j.coph.2014.12.014.","journal-title":"Curr Opin Pharmacol"},{"issue":"11","key":"652_CR32","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"issue":"37","key":"652_CR33","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"issue":"20","key":"652_CR34","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1915928.","journal-title":"N Engl J Med"},{"key":"652_CR35","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2022-5-5","author":"E Kaplinsky","year":"2023","unstructured":"Kaplinsky E, Perrone S, Barbagelata A. Emerging concepts in heart failure management and treatment: focus on vericiguat. Drugs Context. 2023. https:\/\/doi.org\/10.7573\/dic.2022-5-5.","journal-title":"Drugs Context"},{"issue":"5","key":"652_CR36","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ejhf.1432","volume":"21","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, DeMets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21(5):665\u201375. https:\/\/doi.org\/10.1002\/ejhf.1432.","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"652_CR37","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015;314(21):2251\u201362. https:\/\/doi.org\/10.1001\/jama.2015.15734.","journal-title":"JAMA"},{"issue":"6","key":"652_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","volume":"6","author":"CSP Lam","year":"2021","unstructured":"Lam CSP, Giczewska A, Sliwa K, et al. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA Trial. JAMA Cardiol. 2021;6(6):706\u201312. https:\/\/doi.org\/10.1001\/jamacardio.2020.6455.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"652_CR39","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","volume":"8","author":"JA Ezekowitz","year":"2020","unstructured":"Ezekowitz JA, O\u2019Connor CM, Troughton RW, et al. N-terminal Pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail. 2020;8(11):931\u20139. https:\/\/doi.org\/10.1016\/j.jchf.2020.08.008.","journal-title":"JACC Heart Fail"},{"key":"652_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3179","author":"J Ezekowitz","year":"2024","unstructured":"Ezekowitz J, Alemayehu W, Edelmann F, et al. Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial. Eur J Heart Fail. 2024. https:\/\/doi.org\/10.1002\/ejhf.3179.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"652_CR41","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jchf.2023.06.020","volume":"11","author":"CSP Lam","year":"2023","unstructured":"Lam CSP, Pina IL, Zheng Y, et al. Age, sex, and outcomes in heart failure with reduced EF: insights from the VICTORIA trial. JACC Heart Fail. 2023;11(9):1246\u201357. https:\/\/doi.org\/10.1016\/j.jchf.2023.06.020.","journal-title":"JACC Heart Fail"},{"issue":"15","key":"652_CR42","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","volume":"38","author":"B Pieske","year":"2017","unstructured":"Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119\u201327. https:\/\/doi.org\/10.1093\/eurheartj\/ehw593.","journal-title":"Eur Heart J"},{"issue":"15","key":"652_CR43","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","volume":"324","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Lam CSP, Anstrom KJ, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 2020;324(15):1512\u201321. https:\/\/doi.org\/10.1001\/jama.2020.15922.","journal-title":"JAMA"},{"issue":"4","key":"652_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation. 2021;143(4):326\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051783.","journal-title":"Circulation"},{"issue":"21","key":"652_CR45","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"652_CR46","doi-asserted-by":"publisher","first-page":"1335531","DOI":"10.3389\/fendo.2024.1335531","volume":"15","author":"C Chen","year":"2024","unstructured":"Chen C, Lv J, Liu C. Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA. Front Endocrinol (Lausanne). 2024;15:1335531. https:\/\/doi.org\/10.3389\/fendo.2024.1335531.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"652_CR47","unstructured":"Agency EM. VERQUVO\u00ae (vericiguat): EU summary of product characteristics. 2021."},{"issue":"4","key":"652_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40256-022-00538-5","volume":"22","author":"C Kang","year":"2022","unstructured":"Kang C, Lamb YN. Vericiguat: a review in chronic heart failure with reduced ejection fraction. Am J Cardiovasc Drugs. 2022;22(4):451\u20139. https:\/\/doi.org\/10.1007\/s40256-022-00538-5.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"652_CR49","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","volume":"128","author":"VL Roger","year":"2021","unstructured":"Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421\u201334. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318172.","journal-title":"Circ Res"},{"issue":"2","key":"652_CR50","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ehf2.14647","volume":"11","author":"A Olivella","year":"2024","unstructured":"Olivella A, Almenar-Bonet L, Moliner P, et al. Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode. ESC Heart Fail. 2024;11(2):628\u201336. https:\/\/doi.org\/10.1002\/ehf2.14647.","journal-title":"ESC Heart Fail"},{"issue":"19","key":"652_CR51","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.jacc.2018.03.022","volume":"71","author":"DE Forman","year":"2018","unstructured":"Forman DE, Maurer MS, Boyd C, et al. Multimorbidity in older adults with cardiovascular disease. J Am Coll Cardiol. 2018;71(19):2149\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.022.","journal-title":"J Am Coll Cardiol"},{"key":"652_CR52","doi-asserted-by":"publisher","first-page":"164","DOI":"10.24969\/hvt.2022.349","volume":"4","author":"S Cacciatore","year":"2022","unstructured":"Cacciatore S, Spadafora L, Landi F. Orthostatic hypotension in elderly: do you measure orthostatic and clinostatic blood pressure? Heart Vessels Transplant. 2022;4:164\u20137. https:\/\/doi.org\/10.24969\/hvt.2022.349.","journal-title":"Heart Vessels Transplant"},{"issue":"11","key":"652_CR53","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.006977","volume":"13","author":"O Unlu","year":"2020","unstructured":"Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in older adults hospitalized for heart failure. Circ Heart Fail. 2020;13(11): e006977. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.006977.","journal-title":"Circ Heart Fail"},{"key":"652_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.131786","volume":"400","author":"DW Kang","year":"2024","unstructured":"Kang DW, Kang SH, Lee K, et al. Comparative efficacy of vericiguat to sacubitril\/valsartan for patients with heart failure reduced ejection fraction: systematic review and network meta-analysis. Int J Cardiol. 2024;400: 131786. https:\/\/doi.org\/10.1016\/j.ijcard.2024.131786.","journal-title":"Int J Cardiol"},{"issue":"Suppl B","key":"652_CR55","doi-asserted-by":"publisher","first-page":"B140","DOI":"10.1093\/eurheartjsupp\/suad099","volume":"25","author":"G Balestrieri","year":"2023","unstructured":"Balestrieri G, Sciatti E, D\u2019Isa S, D\u2019Elia E, Senni M. Heart failure therapy: the fifth card. Eur Heart J Suppl. 2023;25(Suppl B):B140\u20133. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad099.","journal-title":"Eur Heart J Suppl"},{"issue":"4","key":"652_CR56","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00228-020-03023-7","volume":"77","author":"M Boettcher","year":"2021","unstructured":"Boettcher M, Thomas D, Mueck W, et al. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. Eur J Clin Pharmacol. 2021;77(4):527\u201337. https:\/\/doi.org\/10.1007\/s00228-020-03023-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"652_CR57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.24969\/hvt.2023.388","volume":"11","author":"SC Carla Recupero","year":"2023","unstructured":"Carla Recupero SC, Marco B, Anna MM, Francesco L. Multidisciplinary care for patients with cardiac amyloidosis: a lesson from the 2023 American College of Cardiology Expert Consensus. Heart Vessels and Transplant. 2023;11:78. https:\/\/doi.org\/10.24969\/hvt.2023.388.","journal-title":"Heart Vessels and Transplant"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00652-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00652-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00652-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T07:29:21Z","timestamp":1720510161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00652-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00652-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"8 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Roma La Sapienza within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Luigi Spadafora, Marco Bernardi, Gianmarco Sarto, Beatrice Simeone, Maurizio Forte, Luca D\u2019Ambrosio, Matteo Betti, Alessandra D\u2019Amico, Vittoria Cammisotto, Roberto Carnevale, Simona Bartimoccia, Giuseppe Biondi Zoccai, Giacomo Frati, Sebastiano Sciarretta, Valentina Valenti and Erica Rocco declare they have no potential conflicts of interest that might be relevant to the contents of this manuscript. Pierre Sabouret reports consulting fees from Axis-TV, Astra-Zeneca, BMS, Les Laboratoires Servier, Novartis, Menarini and Sanofi, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"LS conceived the manuscript and drafted the main text with the support of ER and SS. MB and GS reviewed the manuscript and created the figures and tables. BS, MF, LDA, MB, ADA, VC, RC, SB, PS, GBZ, GF and VV provided critical review and conducted extensive bibliographic research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}},{"value":"Data sharing is not applicable to this manuscipt as no datasets were generated.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}